NEIMETH Pharma

[elover]

Thank you all for the education we get here on this site.
I would like to ask if anyone has any info. on Neimeth Pharmaceuticals my
broker bought me some recently and ever since then it has been on a decline
in value.Any hope of it going up?I will apprieciate your contributions here.

[Avocado]

... er, you meant you asked your stockbroker to buy you some, right? You must've had a reason or more to have ordered a buy. Could you share?

Here's a Neimeth, Jan 2007 to date . How recent was your buy?

.

[bwalaman]

If I had to put a name to it, I would equate the NSE Pharmaceutical Sector to a growth / buy and hold sector- this is medium to long term deal.

In fact it is internationally the case... How do Pharmaceuticals make money, if their drugs do well- if they go into new drugs (R&D), major outbreaks etc.

The pharmaceutical sector has the NAFDAC crack down in its favour. And Nigeria is a developing backward country when it comes to health, hygiene, and associated infrastructure (sewage, water systems etc). Couple that, the zero attitudes towards prevention makes the medium – long term prospects are good!!! Sad, but this is business.

So, other than cyclical spikes around AGMs & bonus/dividend speculations, do not expect Banking & Insurance sectors type instant returns. This is not a short term thing.

Do not expect Dangote type returns which is driven by momentum, hype and confidence in the name Dangote (by the way, I believe Dangote companies are sound).

Pack your defensive positions here, especially since you bought it in the high 5 naira range…

In conclusion, check their website… always remember that what is good for the goose, is not necessarily good for the gander- its you call!!!

[bwalaman]

Need their Registrar. Still waiting for my share cert....
Thanks in advance.

[emmany3]

The Registrars to NIEMETH is Meristem Securities along Herbert Macurley Way, Yaba, Lagos. You can walk into their office and present your particulars, possibly, they will attend to you on your certificate.

[bwalaman]

emmany3, Thanks a mil!!!

[Dis GuY]

Anyone one with fundamentals about this company?
I am thinking of adding this to my portfolio for medium/long term
most of the news I found is quite encouraging as they seem to be active and gearing up for bumper profits in the future

the only blemish I found was the case against them with pfizer about the drug trial in Kano

they have lost about 34% in this bear season and I'm looking to buy now

should I wait till it starts recovering or pass

[knightofdelta]

Neimeth is currently doing well in the market because they have spinned off several subsidiaries. I have analyzed the comapny and perssonally I feel it is quite expensive at the current price of N10.67.

Their 3Q results for Dec 31, 2007 showed a PAT of N96 million which is about 357% improvement over the previous corresponding period for N21 million. With outstanding shares of 655 million, their EPS comes to 15K. With linear projections their year end EPS for March 2008 will come to 20K.

At the current price the year end PE is 53.35. That is kinda expensive and going by the average NSE PE of 22, the fair value is around N4.40.

Personally, I am scared of buying Neimeth but who knows, their subsidiaries may do so well and throw my linear projections off tangent. The same thing is currently happening to C&I Leasing though.

Fundamentally, the price is weak for Neimeth but technically, now is a good time to enter because with the way they are going, their year end results is going to be superb and most investors will buy into it once they release their year end results and push up the price above the year high. The problem will now arise if they cannot pay dividends that will match the market price.

The final decision is yours. For me, I will not buy it though it has the potentials for capital gains but I'm scared of market correction. It will be advisable to seek a second opinion before making your final decision. It is your money.

Regards,
The Knight of Delta.

[Dis GuY]

Thanks a lot KoD

That's a very good one, I guess I will watch it for a while

[Dis GuY]

Thinking of entering now, any one with recent information?

[billions]

NEIMETH INTERNATIONAL PHARM PLC
AUDITED RESULT FOR THE YEAR ENDED 31-03-2008
2008 2007
TURNOVER N1.946b N1.503b
PROFIT BEFORE TAXATION N165.130m N172.306m
TAXATION (N66.863m) (N55.891m)
PROFIT AFTER TAXATION N98.267m N116.415m
PROPOSED DIVIDEND 12K PROPOSED BONUS 1 FOR 4
CLOSURE OF REGISTER AUGUST 29TH 2008
PAYMENT DATE TO BE ADVISED LATER

[BLUEMONEY]

Originally Posted by billions

NEIMETH INTERNATIONAL PHARM PLC
AUDITED RESULT FOR THE YEAR ENDED 31-03-2008
2008 2007
TURNOVER N1.946b N1.503b
PROFIT BEFORE TAXATION N165.130m N172.306m
TAXATION (N66.863m) (N55.891m)
PROFIT AFTER TAXATION N98.267m N116.415m
PROPOSED DIVIDEND 12K PROPOSED BONUS 1 FOR 4
CLOSURE OF REGISTER AUGUST 29TH 2008
PAYMENT DATE TO BE ADVISED LATER

The profit is declining. i wonder what is wrong. Though i think the Dividend & Bonus are good.

[dimeji_777]

Neimeth International Pharmaceuticals plc is currently awaiting shareholders’ approval with a view to increase its authorized capital base by 1.2 billion shares and thereafter move to the capital market to raise N10 billion.
If the shareholders concede to this idea and Neimeth scale all regulatory hurdles, the N10 billion is expected to be raised through an hybrid offer of rights issue of 3 billion shares and public offer of 7 billion shares. The price of the offer could not be ascertained but a company source disclosed that the fund raising will hold in the last quarter of the year. Neimeth recently reported an icrease of 29 percent in its audited accounts and report for the year ended March 31, 2008.

The company’s turnover for the period hit N1.95 billion in spite of the growing competition in pharmaceuticals sales.

Officials of the company disclosed that the growth in sales was driven by new products introduction and the activities of its new subsidiary, Neimeth Integrated Services Limited.

However, they observed that profit before tax which was N165 million showed a 4 percent decline over last year, due mainly to the high cost of energy for powering the manufacturing plant and distributing the products across the nation.

The board of directors has recommended a cash dividend of 12 kobo per every 50k share held. In addition, the directors have proposed a script dividend (bonus issue) of one new share for every four shares held. This brings total reward to the shareholders to 24.5k per share, showing a significant 63 percent growth over last year.

It will be recalled that Neimeth has consistently rewarded shareholders with either cash dividend or a mix of cash and bonus issue for seven unbroken years.

In the 2nd half of last year, Neimeth floated two new subsidiaries – Neimeth Integrated Services Limited and Worldwide Health Care Limited as it begins the implementation of a new strategy of transformation into a diversified Health Care Company.

Zak Momodu, vice president human and corporate affairs affirmed that the proceeds of the impending offer would be used to expand the business as well as enhance operational capabilities.

"It will also be used to provide capital for our subsidiaries, go into new businesses as well as enable us to go into proper healthcare business. We aim to establish some mini factories but we are trying not to overstretch ourselves so that we can start giving early returns to our shareholders", he stated

In the out gone year, for example, Neimeth introduced eight new products into the market. Some of the key products launched were Amlovar (Anti-hypertensive), Flucosyd (oral antifungal), Gynotiocosid (topical anti-vaginal candidiasis), Flexodene, (anti- inflammatory/Anti-rheumatism) and Urah (specially formulated topical anti arthritic).

Late last year, Neimeth introduced two new subsidiaries to help drive growth and diversification. One of them – Neimeth Integrated Services has launched into the Nigerian market healthy energy drink Longhorn, in partnership with Multiserve. According to Momodu, "Neimeth is poised to transform into a diversified health care company with interest in core pharmaceuticals, skin and hygiene care, disposable consumables and health drinks".

Over the last seven years, shareholders funds had recorded consistent and impressive growth irrespective of the macro-economic environment.

"As the company’s two subsidiaries go into their first full year of operations, it is expected that shareholders will continue to reap greater benefits in the coming years flowing from the company’s rich pipeline of new products, aggressive business strategies, and the innovative harnessing of potentials in the nitch market areas in the focus of her subsidiaries. The Company’s ECOWAS regional business development has now entered its next phase of "consolidation and expansion" further raising the bar for expected benefits", he noted.

It was gathered that the company had embarked on a re-organisation process with the aim of ceding all pediatrics formulation to Worldwide Healthcare Limited so that Neimeth itself could focus on the core business of manufacturing human and veterinary products.

[hispy99]

Latest Market Info
NEIMETH: HALF YEAR JUNE 30 2008

NEIMETH INTERNATIONAL PHARM. PLC, UNAUDITED RESULT FOR THE PERIOD ENDED 30TH JUNE 2008

TURNOVER 08 N348.890m, 08 N309.716m

PBTAXATION 08 N30.442m, 08 (N58.285m)

TAXATION 08 N9.741m

PATAXATION 08 N20.701m, 08 (N58.285m)

[hispy99]

Latest Market Info
NEIMETH: 6 MONTHS JUNE REPORT 2008
NEIMETH INTERNATIONAL PLC, 6 MONTHS 30-09-2008 2ND QTR FORECAST PPROFIT AND LOSS ACCTS INFORMATION 2008

TURNOVER 08 N1.167b

PROFIT BEFORE TAXATION 08 N152.197m

FORECAST TAXATION 08 (N48.703m)

PROFIT AFTER TAXATION 08 N103m

[ttoladele]

Originally Posted by dimeji_777

Neimeth International Pharmaceuticals plc is currently awaiting shareholders’ approval with a view to increase its authorized capital base by 1.2 billion shares and thereafter move to the capital market to raise N10 billion.
If the shareholders concede to this idea and Neimeth scale all regulatory hurdles, the N10 billion is expected to be raised through an hybrid offer of rights issue of 3 billion shares and public offer of 7 billion shares. The price of the offer could not be ascertained but a company source disclosed that the fund raising will hold in the last quarter of the year. Neimeth recently reported an icrease of 29 percent in its audited accounts and report for the year ended March 31, 2008.

The company’s turnover for the period hit N1.95 billion in spite of the growing competition in pharmaceuticals sales.

Officials of the company disclosed that the growth in sales was driven by new products introduction and the activities of its new subsidiary, Neimeth Integrated Services Limited.

However, they observed that profit before tax which was N165 million showed a 4 percent decline over last year, due mainly to the high cost of energy for powering the manufacturing plant and distributing the products across the nation.

The board of directors has recommended a cash dividend of 12 kobo per every 50k share held. In addition, the directors have proposed a script dividend (bonus issue) of one new share for every four shares held. This brings total reward to the shareholders to 24.5k per share, showing a significant 63 percent growth over last year.

It will be recalled that Neimeth has consistently rewarded shareholders with either cash dividend or a mix of cash and bonus issue for seven unbroken years.

In the 2nd half of last year, Neimeth floated two new subsidiaries – Neimeth Integrated Services Limited and Worldwide Health Care Limited as it begins the implementation of a new strategy of transformation into a diversified Health Care Company.

Zak Momodu, vice president human and corporate affairs affirmed that the proceeds of the impending offer would be used to expand the business as well as enhance operational capabilities.

"It will also be used to provide capital for our subsidiaries, go into new businesses as well as enable us to go into proper healthcare business. We aim to establish some mini factories but we are trying not to overstretch ourselves so that we can start giving early returns to our shareholders", he stated

In the out gone year, for example, Neimeth introduced eight new products into the market. Some of the key products launched were Amlovar (Anti-hypertensive), Flucosyd (oral antifungal), Gynotiocosid (topical anti-vaginal candidiasis), Flexodene, (anti- inflammatory/Anti-rheumatism) and Urah (specially formulated topical anti arthritic).

Late last year, Neimeth introduced two new subsidiaries to help drive growth and diversification. One of them – Neimeth Integrated Services has launched into the Nigerian market healthy energy drink Longhorn, in partnership with Multiserve. According to Momodu, "Neimeth is poised to transform into a diversified health care company with interest in core pharmaceuticals, skin and hygiene care, disposable consumables and health drinks".

Over the last seven years, shareholders funds had recorded consistent and impressive growth irrespective of the macro-economic environment.

"As the company’s two subsidiaries go into their first full year of operations, it is expected that shareholders will continue to reap greater benefits in the coming years flowing from the company’s rich pipeline of new products, aggressive business strategies, and the innovative harnessing of potentials in the nitch market areas in the focus of her subsidiaries. The Company’s ECOWAS regional business development has now entered its next phase of "consolidation and expansion" further raising the bar for expected benefits", he noted.

It was gathered that the company had embarked on a re-organisation process with the aim of ceding all pediatrics formulation to Worldwide Healthcare Limited so that Neimeth itself could focus on the core business of manufacturing human and veterinary products.

Look before you leap.